News Analysis

Pharma funds stand tall amid pandemic, market meltdown

Dhuraivel Gunasekaran | Updated on April 07, 2020 Published on April 07, 2020

Even as otherequity schemes plummeted, pharma MFs contained the fall to a large extent

In the current equity market meltdown amid the pandemic, pharma funds have been the least impacted among equity-oriented mutual funds.

In the period between February 19 and April 3, 2020, the Indian bellwether index, the Nifty 50 TRI, plummeted as much as 30 per cent. Equity mutual funds followed suit. Among the equity-oriented fund categories, pharma funds corrected the least by delivering -11 per cent, followed by MNC (-23 per cent) and ESG funds (-26 per cent). On the other hand, banking, auto and infrastructure funds were hit the most, recording -42, -40 and -35 per cent, respectively.

Of the nine funds in the pharma category, Tata India Pharma & Healthcare, UTI Healthcare and IDBI Healthcare managed to contain the fall well during the period, with returns at -10, -10.1 and -10.4 per cent, respectively, while the sector’s barometer S&P BSE Healthcare Index (TRI) registered -14.3 per cent.

“After a difficult 3-4 years, pharma sector valuations have corrected and become attractive,” said Sailesh Raj Bhan, Deputy CIO - Equity Investments, Nippon India Mutual Fund. “Even in the recent crisis due to the coronavirus, the pharma sector is among the very few sectors with an improving growth outlook. Also, the institutional ownership in the sector is very low and rising investor interest will be a major positive for the performance of this sector.”

 

 

Multiple headwinds

After a commendable performance until 2015, the Indian healthcare sector faced multiple headwinds, both in the domestic and global markets. Regulatory overhang and price erosion in primary drugs in key markets have weighed on the stocks of Indian pharma companies.

However, the performance in recent quarters indicates a turnaround in the fortunes of the sector. Waning price erosion in the US market, traction in emerging market businesses, better performance in the domestic market and low volatility in the rupee aided revenue growth.

Among the constituents in the BSE Healthcare index, Panacea Biotec, Abbott India, Cipla, Cadila Healthcare and Ajanta Pharma were the stocks that fell the least (returns ranging from 8 per cent and -1 per cent) in the above mentioned period. Shalby, Wockhardt, Jubilant Life Sciences and Aster DM Healthcare were the laggards (returns ranging from -45 per cent to -60 per cent).

 

 

Will this trend sustain?

“The ongoing pandemic is unprecedented and has clearly put a large strain on the healthcare system across the globe,” said Vrijesh Kasera, Fund Manager, Mirae Asset Healthcare Fund. “While the cure seems some time away, overall sales of pharma companies will continue as it is, drugs being a necessity. Thus, while the majority of the other non-essential businesses are impacted, pharma companies’ sales will continue doing relatively better than other sectors.”

“In the current scenario, as selective surgeries to the extent possible are being postponed and there is a reduction in OPD consultations, there will be some impact on the utilisation and profitability. However, the sector impact remains limited versus the other sectors. It is too early to comment on the same, but the current pandemic does call for an increase in spending on healthcare, for both the government and consumers, to prepare and guard against any such event in the future,” Kasera added.

Published on April 07, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.